The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

Among older adults and adults with low atherosclerotic cardiovascular disease risk, use of aspirin decreased after 2019.

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance ...

A new study published in the Nature Scientific Reports highlighted the potential benefits of aspirin in reducing biochemical recurrence (BCR) rates following robot-assisted radical ...

Three-year results from the ALASCCA trial (NCT02647099), presented at the 2025 ASCO Gastrointestinal Cancer Symposium, showed ...

A recent study conducted by the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) found that mislabeled NSAID ...

Scientists at UMass Amherst and Ernest Pharmaceuticals developed BacID, a bacterial cancer therapy activated by aspirin. This ...

Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living with severe acute pain, while reducing the effects ...

Expected to begin in 2027, the trials will involve human patients, and the researchers are working to obtain the necessary ...

In recognition of January 23rd as Maternal Health Awareness Day, the Preeclampsia Foundation in partnership with Patients & Purpose announc ...